These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2771141)

  • 1. [Ciclopiroxolamine in the topical treatment of vaginal mycoses].
    Bucciero A; Molteni E; Molteni B; Mariani W; Jacobellis M
    Minerva Ginecol; 1989 Jun; 41(6):283-6. PubMed ID: 2771141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Open clinical study on the efficacy and tolerance of ciclopiroxolamine in vulvovaginal candidosis (author's transl)].
    Peil HG
    Arzneimittelforschung; 1981; 31(8A):1366-8. PubMed ID: 7028048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A clinical study of cyclopyroxolamine versus clotrimazole in the treatment of mycotic vulvovaginitis].
    Giannoni M; Pollastro M; Jacobellis M
    Minerva Med; 1990; 81(7-8):555-9. PubMed ID: 2199853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The treatment of acute mycotic colpitis with ciclopiroxolamine in patients using oral contraceptives].
    Damianov L; Novachkov V; Ivanov S
    Akush Ginekol (Sofiia); 1997; 36(1):32-3. PubMed ID: 9289960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Topical application of a 0.1% ciclopiroxolamine solution for the treatment of pityriasis versicolor].
    Corte M; Jung K; Linker U; Martini H; Sapp-Boncelet I; Schulz H
    Mycoses; 1989 Apr; 32(4):200-3. PubMed ID: 2755466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The treatment of acute mycotic colpitis with ciclopiroxolamine (Dafnegin-CSC) in pregnant patients in the 10th lunar month].
    Novachkov V; Damianov L; Tsankova M; Ivanov S
    Akush Ginekol (Sofiia); 1999; 38(4):54-5. PubMed ID: 10726357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multicenter evaluation of the activity and tolerance of a new antimycotic agent: ciclopiroxolamine].
    Cattaneo M; Betti R; Lodi A; Masnada MC
    G Ital Dermatol Venereol; 1986; 121(6):LXXXI-LXXXV. PubMed ID: 3557531
    [No Abstract]   [Full Text] [Related]  

  • 8. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
    Mendling W; Brasch J; Cornely OA; Effendy I; Friese K; Ginter-Hanselmayer G; Hof H; Mayser P; Mylonas I; Ruhnke M; Schaller M; Weissenbacher ER
    Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society.
    Mendling W; Brasch J; ; ; ;
    Mycoses; 2012 Jul; 55 Suppl 3():1-13. PubMed ID: 22519657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical tioconazole versus systemic ketoconazole treatment of vaginal candidiasis.
    Rohde-Werner H
    J Int Med Res; 1984; 12(5):298-302. PubMed ID: 6094282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Controlled clinical study of cyclopyroxolamine in vaginal candidiasis].
    Jasonni VM; La Marca L; Naldi S; De Paoli L; Flamigni C
    Minerva Ginecol; 1989 Aug; 41(8):417-9. PubMed ID: 2812494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical fenticonazole in dermatology and gynaecology: current role in therapy.
    Veraldi S; Milani R
    Drugs; 2008; 68(15):2183-94. PubMed ID: 18840006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Open clinical trial in dermal mycoses of a 1% ciclopiroxolamine solution in polyethylene glycol 400 carried out in FR Germany/Study with shortened therapy (author's transl)].
    Torres J; Savopoulos C; Dittmar W
    Arzneimittelforschung; 1981; 31(8A):1373-6. PubMed ID: 7028049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 0.8% and 1.6% terconazole cream in severe vulvovaginal candidiasis.
    Schmitt C; Sobel J; Meriwether C
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):414-6. PubMed ID: 2381618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cyclopiroxolamine (HOE 296), new antimycotic substance, in superficial mycosis].
    Aratari E; Virno G; Persi A
    G Ital Dermatol Venereol; 1983; 118(1):I-VI. PubMed ID: 6358001
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized prospective comparative study: short-term treatment with ciclopiroxolamine (cream and solution) versus boric acid in the treatment of otomycosis.
    del Palacio A; Cuétara MS; López-Suso MJ; Amor E; Garau M
    Mycoses; 2002 Oct; 45(8):317-28. PubMed ID: 12572722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The treatment of mycotic colpitis with the preparation Batrafen].
    Grozdanov G; Krumov G; Milchev N
    Akush Ginekol (Sofiia); 1993; 32(1):47-8. PubMed ID: 8172352
    [No Abstract]   [Full Text] [Related]  

  • 18. Butoconazole nitrate 2% for vulvovaginal candidiasis. New, single-dose vaginal cream formulation vs. seven-day treatment with miconazole nitrate. Gynazole 1 Study Group.
    Brown D; Henzl MR; Kaufman RH
    J Reprod Med; 1999 Nov; 44(11):933-8. PubMed ID: 10589403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mycotic vulvovaginitis and topical cyclopiroxolamine].
    Nencioni T; Pamparana F; Jacobellis M
    Minerva Ginecol; 1988 Dec; 40(12):719-22. PubMed ID: 3072493
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of single administration with an ovule of 600 mg fenticonazole versus a 500 mg clotrimazole vaginal pessary in the treatment of vaginal candidiasis.
    Wiest W; Azzollini E; Ruffmann R
    J Int Med Res; 1989; 17(4):369-72. PubMed ID: 2676652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.